𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Arylamine N-Acetyltransferase 1: A Novel Drug Target in Cancer Development

✍ Scribed by Butcher, N. J.; Minchin, R. F.

Book ID
111949447
Publisher
American Society for Pharmacology and Experimental Therapeutics
Year
2011
Tongue
English
Weight
562 KB
Volume
64
Category
Article
ISSN
0031-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Arylamine N-acetyltransferase 1 expressi
Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: A potential marker in estrogen receptor-positive tumors
✍ Larissa Wakefield; James Robinson; Hilary Long; J. Claire Ibbitt; Susanna Cooke; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 251 KB

## Abstract The prognosis for patients with estrogen receptor (ER)‐positive breast cancer has improved significantly with the prescription of selective ER modulators (SERMs) for ER‐positive breast cancer treatment. However, only a proportion of ER‐positive tumors respond to SERMs, and resistance to

BMI1 as a novel target for drug discover
BMI1 as a novel target for drug discovery in cancer
✍ Liangxian Cao; Jenelle Bombard; Katherine Cintron; Josephine Sheedy; Marla L. We πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 889 KB

Growing evidence has demonstrated that clonogenic cancer stem (initiating) cells are responsible for tumor regrowth and disease relapse. Bmi-1 plays a critical role in the self-renewal of adult stem cells. The Bmi-1 protein is elevated in many types of cancers, and experimental reduction of Bmi-1 pr